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ABSTRACT 
 
 
Lewis, David M.S., Purdue University, August 2013. Soypeptide Lunasin in Cytokine 
Immunotherapy for Lymphoma. Major Professor: Hua-Chen Chang. 
 
 
Immunostimulatory cytokines can enhance anti-tumor immunity and are part of the therapeutic 
armamentarium for cancer treatment. We previously reported that chemotherapy-treated 
lymphoma patients acquire a deficiency of Signal Transducer and Activator of Transcription 4 
(STAT4), which results in defective IFNγ production during clinical immunotherapy. With the goal 
of further improvement in cytokine-based immunotherapy, we examined the effects of a 
soybean peptide called lunasin that exhibits immunostimulatory effects on natural killer cells 
(NKCs). Peripheral blood mononucleated cells (PBMCs) from healthy donors and chemotherapy-
treated lymphoma patients were stimulated with or without lunasin in the presence of IL-12 or 
IL-2. NK activation was evaluated, and its tumoricidal activity was assessed using in vitro and in 
vivo tumor models. Chromatin immunoprecipitation (ChIP) assay was performed to evaluate the 
histone modification of gene loci that are regulated by lunasin and cytokine. Adding lunasin to 
IL-12- or IL-2-cultuted NK cells demonstrated synergistic effects in the induction of IFNG and 
genes involved in cytotoxicity. The combination of lunasin and cytokines (IL-12 plus IL-2) was 
capable of restoring IFNγ production by NK cells from post-transplant lymphoma patients. In 
addition, NK cells stimulated with lunasin plus cytokines have higher tumoricidal activity than 
those stimulated with cytokines alone using in vitro tumor models. The underlying mechanism 
responsible for the effects of lunasin on NK cells is likely due to epigenetic modulation at target 
gene loci. Lunasin represents a different class of immune modulating agent that may augment 
the therapeutic responses mediated by cytokine-based immunotherapy.
1 
CHAPTER 1: LITERATURE REVIEW
 
 
1.1 Introduction 
Natural Killer cells (NKCs) are an important part of the innate immune system particularly as 
they pertain to early defense against tumor malignancy. Understanding the circumstances in 
which NKCs are most active, and specifically what artificial or endogenously produced 
modulators affect their activity greatly benefits cancer research. The soypeptide lunasin has, in 
recent years, been described as a chemopreventative agent, and has been researched largely as 
a direct treatment for cancerous or potentially cancerous cells. In this study we explore lunasin 
as modulator of NKC activity. The purpose of this review is to provide a general background of 
NKCs, what is known about their mechanism of action, what stimulates them, their relationship 
to tumor cells, and how they can be used in immunotherapy. A special focus will also be placed 
on the background of the soypeptide lunasin which is explored as an immunomodulating agent 
of NKCs following the literature review. 
 
1.2 NK Cell Biology 
NKCs are large granular lymphocytes that represent about 15% of peripheral blood lymphocytes. 
When NKCs were first identified nearly 40 years ago it was observed that they did not require 
prior sensitization to kill target cells. They could spontaneously, or naturally, attack their targets 
and so were termed natural killer cells [1, 2]. It has since been established that NKCs are able to 
identify “missing self” due largely to the absence of major histocompatibility complex (MHC) I 
molecules[3]. MHC I is ubiquitously expressed on all nucleated cells in the mammalian body. 
One of its functions is to present antigens to CD8+ T cells, but another is to act as a ligand for 
inhibitory NKC receptors thus identifying targeted cells as originating from the same 
environment as NKCs, or “self” [4]. NKCs can be parsed into subsets identified as CD56bright and 
CD56dim which are superior cytokine producers and cytotoxic cells respectively [2, 5]. The 
breadth of known NKC receptors and their ligands is still being explored, but what is clear is that 
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NKC function is as complex and daunting a subject as any part of the adaptive immune system. 
NKCs are of particular interest to researchers pursuing immunotherapy. Their ability to survey 
the body and find cells that are “missing self” gives them several advantages over adaptive 
immunity. Adaptive immunity is dominated by B and T cells, which require gene rearrangement 
to create a highly specific receptor. When this highly specific receptor finds a corresponding 
antigen the B or T lymphocyte will duplicate itself via clonal expansion in order to develop 
enough cells for an adaptive immune response, a process that can take a minimum of several 
days to occur [6]. The most obvious advantage of the innate actions of NKCs over adaptive 
immunity is the speed at which NKC can react. The expedient responses of NKCs to foreign 
antigen allow them to halt, or at least slow, the progression of viral infections and tumorous 
mutations until an adaptive response can be mounted. Gaining control over these innate 
abilities could allow cancer researchers to prevent the recurrence of tumors after patients have 
undergone chemotherapy or even augment the immune system of individuals at risk for cancer  
 
1.3 Recognition of Targets by the NKC: the “Missing self” Model 
The “missing self” model proposes that NKCs primarily target cells with either reduced or absent 
MHC I expression (Figure 1). MHC I is ubiquitously expressed on all nucleated cells in the 
mammalian body; one of its functions is to present antigens to cytotoxic T lymphocytes (CTL), 
but another is to identify cells as “self” or originating from the same environment as NKCs [4]. 
Generally it has been noted that cells expressing MHC I molecules are better able to inhibit 
destruction by NKC [3] through the engagement of inhibitory receptors. Cancerous cells often 
have altered or reduced MHC I expression, which cannot trigger an inhibitory signal in NKC, and 
thus these cells are often more susceptible to NKC-mediated killing. 
 
1.4 Licensing NKC to Engage Targets 
Recent studies have suggested that NKCs must first become “licensed” before they actively 
defend against “missing self” cells [7, 8]. MHC I is the ligand for many inhibitory NKC receptors. 
NKCs developed from environments lacking MHC I, such as B2m -/- mice, cannot successfully 
target virally infected or tumorous cells derived from the same host [8-10]. This is interesting 
because early versions of the “missing self” hypothesis predicted that NKCs would attack any 
cell without MHC I proteins. That NKCs don’t become autoreactive in an environment 
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completely null of MHC I protein indicates that they must somehow need the molecule. They 
need to be “licensed” to survey for “missing self”. In support of this idea, one study showed that 
NKCs with Ly49A receptors (specific for H-2d haplotype) were inactive within B6 mice (H-2b 
haplotype), while Ly49C+ NKCs (specific for H-2b haplotype) were active [10]. Given that Ly49, 
and their human equivalent KIR, Killer immunoglobulin-Like receptors, are highly polymorphic it 
might be expected that many NKCs would not be in an environment with the appropriate MHC 
ligand and would become autoreactive. If, however, licensing is required for activation, NKCs 
that don’t have a ligand for their receptor would simply remain unlicensed and inert. Unlicensed 
cells represent an NKC population that is, under normal conditions, fully developed but 
otherwise unresponsive to activation. The differences between licensed and unlicensed cells 
seem to diminish under inflammatory conditions when the cytokines are present [10]. This 
supports a model in which licensed NKC avoid autoreactivity due to inhibitory ligands and 
unlicensed NKCs avoid autoreactivity due to being inert until infection occurs, while both are 
relevant to a healthy immune response. 
 
1.5 Signaling Pathways Mediated by the Interaction of NKC Receptors and Their Ligands 
The activity of NKC is now known to be regulated by the net signaling events triggered by 
activating and inhibitory receptors that recognize the ligands on target cells. When an inhibitory 
receptor bearing an ITIM (immunoreceptor tyrosine based inhibitory motif) is ligated the 
tyrosine of the ITIM is phosphorylated, often by a Src kinase, which provides a binding site for 
phosphatases with Src homology 2 (SH2) domains, like SHIP and SHP-1, which then can act in a 
number of inhibitory pathways [11, 12]. For an activating pathway to be initiated the activating 
receptor must be associated with an ITAM (immunoreceptor tyrosine based activation motif) 
[13]. Upon engagement of its ligand, a tyrosine residue on the ITAM becomes phosphorylated 
which in turn activates Syk or ZAP-70, allowing them to activate a number of signaling pathways 
[13, 14].  
Both activating and inhibiting receptors are engaged whenever an NKC encounters a target cell. 
If enough activating receptors are ligated the inhibitory signal can be overcome and the cell will 
be targeted, if not then the inhibitory signal will prevail and the cell will be recognized as “self” 
(Figure 1). It’s important to note that a lack of inhibition doesn’t necessarily mean the NKC will 
engage a target. Erythrocytes for example lack nuclei and thus MHC I molecules, and neural 
4 
tissues have relatively low MHC I expression levels but neither is attacked by NKCs under normal 
circumstances [13]. Thus NKCs require an activating signal and not only a lack of inhibitory 
signals. 
NKC receptors can be grouped into several broad categories including the Killer 
immunoglobulin-Like receptors (KIR), the C-type Lectin superfamily (CLR), natural cytotoxicity 
receptors (NCR) [32], Fc receptors and cytokine receptors. 
 
1.5.1 Killer Immunoglobulin-Like Receptors (KIR) 
KIR are polymorphic receptors, evolved from the Ig superfamily, that recognize HLA-A, B, and C 
proteins [4]. Individual NKCs inherit only some of the many potential KIRs, but at least one will 
usually be specific for a host MHC I molecule [15, 16]. An inhibitory and activating KIR can share 
the same specificity, but Inhibitory KIRs tend to have a greater avidity for their targets. This is 
why if both inhibitory and activating KIRs are ligated, the inhibitory signal will be stronger and 
the NKC will be pacified [17]. KIR’s basic form and activating or inhibitory pathway is denoted in 
how they are named. KIR2DL, for instance, has 2 Ig like domains (2D) and an additional long 
cytoplasmic domain (L) which will contain at least one ITIM sequence. KIR2DS on the other hand 
has 2 Ig like domains (2D) and an additional short cytoplasmic domain (S) which means the 
receptor will need an accessory protein with an ITAM, like DAP12, in order to send activating 
signals (Figure 2) [4].  
 
1.5.2 C-type Lectin Superfamily (CLR) 
NKG2 (NK group 2) and CD94 are transmembrane proteins from the CLR which are often 
associated with one another and can either be activating or inhibitory. CD94 and NKG2A, for 
instance, are known to covalently bind to one another forming a heterodimeric receptor specific 
for the HLA-E haplotype, and because NKG2A has an ITIM motif it relays an inhibitory signal [12, 
18, 19]. NKG2C, conversely, works through an ITAM via its association with adaptor protein 
DAP12 which serves to contain the ITAM and stabilizes the NKG2C-DAP12 complex [13]. Despite 
their opposite effects, NKG2A and NKG2C share a common ligand in HLA-E [13, 19]. This is 
noteworthy because NKG2A has a much higher binding affinity for HLA-E [20]. This means that if 
the two receptors were ligated at the same time the inhibitory signal would be stronger 
suggesting a possible evolutionary mechanism to prevent autoimmunity due to NKC activity. 
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NKG2D is unique in the NKG2 family. NKG2 A, C, and E all share a similar genetic sequence, are 
ligated by HLA-E , and form heterodimers with CD94 [21]. NKG2D, however, is genetically 
distinct, is ligated by stress induced non-classical MHC proteins like MICA and MICB, and does 
not form a dimer with CD94 [4, 21-23]. Additionally rather than using DAP12’s ITAM, NKG2D-
triggered cytotoxic activity is mediated via DAP10, which associates with NKG2D in a 
heterocomplex [24]. NKG2D is a potent activating receptor and can overcome signals from 
inhibitory KIRs [25, 26]. In addition to MICA/B, NKG2D can also be ligated by ULBP (UL binding 
proteins) [21, 26]. As a testament to the evolutionary age and importance of the NKG2D 
receptor several diseases seem to have evolved specific defenses against it. It has been 
suggested that UL 16, a human cytomegalovirus protein, can bind to ULBPs (UL Binding Proteins) 
1-2 and MICB, effectively preventing or retarding NKG2D activation [27].  
 
1.5.3 Natural Cytotoxicity Receptors (NCR) 
Natural cytotoxicity receptors (NCR) are a group of receptors, belonging to the Ig superfamily, 
involved in many NKC activation events. The group is currently comprised of three receptors 
including NKp46, NKp30, and NKp44. NKp46 is thought to be important in the destruction of HLA 
deficient tumor cells. Studies have shown that NKCs expressing higher levels of NKp46 
(NKp46bright) are better able to lyse HLA negative targets [28]. NKp46 cannot signal on its own 
but does associate with adaptor proteins, CD3ζ and FCεRIγ, which signal though ITAMs [29]. 
NKp44 is only present on activated NKCs, signals through a DAP12 mediated pathway, and is 
ligated by non-classical MHC molecules [30]. When NKp44 is blocked along with NKp46 it 
appears to have a greater inhibitory affect than if either one is blocked alone [30]. This suggests 
that the two could work in a synergistic fashion. NKp30 expression correlates with NKp46, in 
that both are present on all active and resting NKCs [31]. It has been noted that NKp30 and 
NKp46 have impaired expression in HIV patients possibly contributing to the increased 
occurrence of opportunistic tumors [32]. It has also been noted that in certain melanoma cell 
lines the masking of both NKp30 and NKp46 will decrease cytotoxic activity in freshly isolated 
NKC more than masking either alone [31], again suggesting that NCRs work in a synergistic 
fashion. 
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1.5.4 Fc Receptors 
CD16, also known as FcγRIIIA, is the receptor responsible for antibody dependent cell 
cytotoxicity (ADCC) in NKCs. The receptor associates with either or both CD3ζ, and FcεRIγ, which 
are ITAM bearing adaptor proteins [4, 14]. When it comes into contact with cell with an IgG 
attached to its surface, CD16 is ligated by the Fc region of the IgG, which initiates the activation 
of the NKC and leads to the destruction of the target cell [33, 34]. 
 
1.5.5 Cytokine Receptor Signaling and the JAK/STAT Pathway 
Cytokine regulation of NKCs is primarily mediated through JAK/STAT signaling pathways. When a 
receptor on the NKC encounters its cytokine there is a conformation change in the receptor 
which leads to the activation of JAK (janus kinase). The JAK will phosphorylate a tyrosine residue 
on the intracellular portion of the receptor creating a binding site for STAT (signal transducers 
and activators of transcription) [35]. STAT will bind to the receptor and be phosphorylated by 
JAK after which it will dimerize with another STAT and translocate to the nucleus where it 
activates transcription on target genes (Figure 3). In mammals the JAK family currently has four 
members including JAK1, JAK2, JAK3, and Tyk2 [36] and seven different STATs [35]. Different 
receptor families will utilize different JAK/STAT pathways (Figure 4). The IL-12R, for instance, is a 
member of the gp130 family and signals though a JAK2,Tyk2 / STAT4 pathway while IFNγRI is a 
member of the IFN family and signals via JAK1,JAK2/ STAT1 [35].  
 
1.5.6 The Evasion of Immune Surveillance 
NKCs have evolved into a unique role in immune system. When some viruses, for instance, enter 
a cell they are thought to down regulate MHC I expression [37]. It has been shown that 
adenovirus-2 encodes a protein, E19, which inhibits the transport of MHC I molecules to the 
cells surface [38]. By doing so the virus has effectively protects itself from attacks by CTL which 
rely on peptide presentation by MHC I molecules to clear pathogens. Tumor cells similarly tend 
to have decreased MHC I expression, as tumors which do express MHC will be targeted by T cells 
[37]. NKCs have receptors, like KIR and NKG2A, which exist specifically to survey for cells with 
altered MHC expression, making virally infected and tumor cells their prime targets. Viruses are 
constantly adapting to the human immune system and have, over time, evolved defenses 
against both T cells and NKCs. HIV (human immunodeficiency virus) is one of the most 
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successful. Much of the NKC’s success in identifying target cells comes from its ability to 
recognize absent or altered HLA-C, via KIR receptors, and HLA-E proteins via NKG2D:CD94 
receptors [4, 21]. HIV is reported to be able to down regulate HLA-A and HLA-B while HLA-C and 
HLA-E remain unaffected [39]. This allows HIV to effectively avoid both T and NKCs. Certain 
tumors have also been shown to have NKC evasion tactics. Tumors from human patients with 
stomach, colon, and rectal cancers were shown to produce high levels of soluble MICA which 
serves to provide alternative targets for NKG2D bearing immune cells [40]. These selected 
defenses against NKG2D and other NKC receptors are indicative of their utility and importance 
to the immune system. 
 
1.6 Natural Killer Cell Subsets 
Human NKCs are characterized as being CD 56+ and CD3- but beyond that they can be divided 
into subsets with specific functions and surface receptors. CD56
high
CD16
low
 cells represent 
approximately 10% of NKCs and produce cytokines at higher levels than CD56
low
 CD16
high
 cells in 
response to cytokines, such as IL-12, IL-15, and IL-18 [33, 41]. CD56dim CD16bright NKCs 
represent a majority of NKCs in the peripheral blood and produce fewer cytokines but are more 
cytotoxic than their CD56brightCD16dim counterparts [33].  
 
1.7 Functions of NKCs 
 
1.7.1 Immune Regulatory Function 
NKCs regulate the immune responses by producing a number of cytokines and chemokines, 
including interferon gamma (IFNγ), tumor necrosis factor (TNFα), and granulocyte/macrophage 
colony stimulating factor (GM-CSF, CSF2) [42-44]. IFNγ is important to the immune system’s 
response to a variety of tumors and virally infected cells [45-47]. IFNγ activates cytotoxic T 
lymphocytes (CTL) and macrophages in response to infection [48], retards tumor growth [49, 
50], and, along with TNFα, stimulates the maturation of dendritic cells [51]. In addition, IFNγ 
enhances the immunogenicity of tumor cells by upregulating the MHC class I and class II 
expression which allows them to be recognized and eliminated by T cells more easily [52, 53]. 
Both spontaneously arising and chemically-induced tumors are more common in IFNγ receptor- 
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deficient and IFNγ-deficient mice compared to wild-type mice [54-57]. The Inhibition of IFNγ in 
vivo abrogates the ability of immunocompetent mice to reject transplanted syngeneic tumors 
[57].  
Along with cytokines NKCs are known to produce chemokines including CCL3, CCL4, CCL5, 
CCL22, and CXCL8 when activated. It is thought that the production of these chemokines serves 
to attract T cells, B cells, and other NKCs to the vicinity of the active NKC [58]. One study showed 
that NKCs incubated with K562, chronic myelogenous leukemia, produced more CCL3, 4, and 5 
as compared to NKCs alone, resulting in recruiting bystander NKCs [59]. 
 
1.7.2 Cytolytic Function 
In addition to their immunoregulatory role through cytokine production, NKCs have the ability 
to spontaneously kill target cells without any prior immunization or stimulation. NKCs, in a 
process referred to as immunosurveillance, survey the body for foreign and mutated cells using 
an of array activating and inhibitory receptors. Upon recognition, NKCs are able to induce 
apoptosis in their targets. Apoptosis is a distinctive mode of programmed cell death necessary 
for the survival of living organisms. There are two main pathways of apoptosis referred to as 
intrinsic, in which an apoptotic suppressor within the cell itself is damaged due to external 
factors like radiation or toxins, and extrinsic, in which a receptor on the cell surface is ligated 
activating a “death domain”. 
 
1.7.2.1 Fas and FasL Mediated Apoptosis 
NKCs and CTLs (Cytotoxic T Lymphocytes) can utilize the extrinsic method or an additional 
method which requires the production of lytic granules containing granzymes and perforin. One 
of the better defined death domain pathways requires the Fas receptor. In this pathway a FasL 
on the immune cell will ligate a Fas receptor on the target cell. The ligation will trigger the 
binding of FADD, an adaptor protein, which will in turn associate with procaspase-8. A DISC, the 
death inducing signaling complex, will then form and cleave procaspase-8 leading to its 
activation, followed by the activation of caspase-3, a potent catalyst in the cleavage of key 
cellular proteins, ultimately leading to cell death [60-63] (Figure 5).  
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1.7.2.2 Release Lytic Granules 
When an NKC or CTL encounters a target cell they can release granules, containing granzymes 
and perforin. Of the five known human granzymes, Granzyme B has the best understood 
pathway. It appears to induce apoptosis through a number of methods including direct 
activation of caspase-3, and the activation of caspase -10 which leads to the activation of 
caspase-3 [63] (Figure 6). There is also evidence showing that granzyme B can work though 
mitochondrial pathways involving the disruption of the mitochondrial membrane, leading to the 
release of pro-apoptotic proteins, and the release of cytochrome c, which activates caspase-9 
leading to the activation of caspase-3 and apoptosis[63, 64] (Figure 6). Perforin is generally 
recognized as providing the mechanism for granzyme to enter the cell, though the exact method 
through which it does this remains a subject of debate [65]. Knockout experiments indicate that 
mutations in the perforin genes can be detrimental to the immune system, particularly in 
regards to tumor immunosurveillance. It has been shown that perforin deficient mice are unable 
to prevent the metastases of tumors [66]. In a similar study it was observed that perforin 
deficient mice develop larger tumors at a faster rate when challenged with a number of cell lines 
[67]. 
 
1.8 NKC-Based Cancer Immunotherapy 
In a process referred to as immunosurveillance NKCs survey the body for foreign and mutated 
cells using an array of activating and inhibitory receptors. Harnessing this ability has been a long 
time goal for cancer researchers. A number of strategies have been used to manipulate NKC 
activity in an effort to enhance cancer immunotherapy. It is unlikely that any one method will 
become the new mainstay of cancer treatment. The future of immunotherapy will undoubtedly 
be a combination of different immunological and oncological practices.  
 
1.8.1 Blocking Inhibitory Signals on NKC 
One method involves blocking inhibitory receptors, so that NKCs will more readily attack cancer 
cells. It has been reported that the blocking of murine Ly49C, an NKC inhibitory receptor 
comparable to human KIR, with F(ab’) monoclonal antibody fragments can decrease tumor size 
and increase the survival rate of mice [68].  
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1.8.2 Engagement of Activating Signals on NKC 
Another study found that using rituximab, an anti CD20 mAb, to mark CD20+ lymphoma 
significantly enhances the ability of NKCs to identify and attack lymphoma tumors [69]. This is 
due to the NKC’s CD16 receptor which can recognize the Fc portion of the antibody allowing the 
NKCs to attack the lymphoma cells in ADCC. The manipulation of NKC receptors is an exciting 
new area of research which could extend into epigenetic silencing of inhibitory receptor 
expression with siRNA, the overexpression of activating receptors, or the creation of chimeric 
receptors specific for tumor ligands [15, 70]. 
 
1.8.3 Adoptive NKCs Transfer and Bone Marrow Transplantation 
Adoptive cell transfer is an approach to immunotherapy which requires the isolation and 
expansion of either autologous or allogenic immune cells followed by infusion back into the 
patient. The appeal of this method is that, in theory, immune cells specific to the cancer in 
question can be selected for ex vivo and expanded free from endogenous controls [71]. An 
extension of this idea is to use NKCs that don’t respond to the same inhibitory ligands as the 
patients, which is the premise behind utilizing the graft versus leukemia (GvL) effect. For 
instance, a patient undergoing a bone marrow transplant needs new hematopoietic stem cells, 
which they will receive from a donor. Ideally the donor would have HLA antigens that are 
identical to the recipient’s and the graft would avoid rejection and avoid attacking healthy host 
cells in what is called graft versus host disease (GvHD). NKCs have inhibitory KIR receptors with 
HLA ligands [15]. If an individual has an HLA-C haplotype, for instance, then they will likely have 
HLA-C specific KIR on their NKCs. If these cells are transferred to a patient with a different 
haplotype, whose own immune system would have been destroyed as a part of cancer 
treatment, the NKCs would attack any remaining leukemia cells because they do not have the 
HLA-C protein to ligate the inhibitory KIR receptor, this is the GvL effect [72]. Additionally the 
NKCs would attack any of the host’s remaining dendritic cells, which could generate GvHD by 
presenting alloantigens to donor T cells [73, 74]. This thinking is supported by studies showing 
that AML (Acute Myeloid Leukemia) patients have higher remission rates when receiving KIR 
mismatched adoptive NKCs transfers [75].  
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1.9 NKC-Stimulating Agents 
1.9.1 Cytokine Stimulation in Natural Killer Cells 
Cytokine stimulation is an attractive immunotherapeutical option because it enhances the 
cytotoxicity of already established NKC populations rather than introducing new cells in an 
adoptive transfer and risking rejection. IL-2 has been clinically shown to enhance immune 
function in patients presenting with a variety of cancers [76, 77]. The ex vivo stimulation of NKCs 
with an IL-12, IL-18 combination in known to effectively increases NKC activity against MLL-3 
leukemia cells, which express a wide range of inhibitory KIR ligands [78]. 
The cytotoxicity of NK cells can be activated by various cytokines and interferons which are 
often produced by monocytes or dendritic cells (DC). IFN α and β, enhance NKC cytotoxicity, and 
induce proliferation [46, 79, 80]. IL-2 and IL-12 can upregulate the expression of granzyme B by 
NK cells, resulting in increased cytolytic activity [81]. The combination of IL-12 and IL-18 is a 
potent inducer of IFNγ, particularly in CD56 bright cells, and combination of IL-15 and IL-18 has 
been noted as an inducer of GM-CSF in NKCs [82].  
 
1.9.2 Natural Additive Stimulation in Natural Killer Cells 
 
1.9.2.1 Mushrooms 
Mushrooms, a food common to the palate of many cultures, have long suspected of having 
hidden health benefits. The white button mushroom, Agaricus bisporus, is commonly eaten in 
the U.S. and has considerable immunostimulatory effects. It has been shown, in mice, to 
increase IFNγ and TNFα production by NK and Th1 cells [83]. Similarly, a mushroom extract, 
Agaricus blazei Murill Kyowa, has been observed to increase NKC activity in gynecological cancer 
patients undergoing chemotherapy [84]. In another study D-Fraction, a β glucan extracted from 
the maitake mushroom Grifola frondosa, was shown to increase IFNγ and TNFα production by 
NKCs [85]. 
 
1.9.2.2 Other Food Products 
In addition to mushrooms there are other NKC modulating additives. MGN-3 is a modified 
arabinoxylan derived from rice bran that is known to enhance murine NK activity [86]. 
Curcumin, a yellow pigment from the Indian herb Curcuma longa , has been identified as an 
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enhancer of NKC cytotoxic activity and is able to reverse some of the immunosuppressive effects 
of tumors on NKC [87, 88]. In a double blind study it was shown that terminally ill cancer patient 
receiving AGE (aged garlic extract) over the course of three months had a statistically significant 
higher number of NKCs [89].  
 
1.10 Lunasin 
 
1.10.1 Lunasin structure 
Lunasin is a 43 amino acid peptide that was first isolated from the soybean and is now known to 
be present in wheat, barley, and other staple crops [90]. It was originally cloned as cDNA from a 
small-subunit peptide of the S2 albumin (Gms2S-1) [91]. Lunasin has been recognized to have an 
RGD (Arginine, Glycine, Aspartic acid) adhesion motif which is believed to facilitate the 
internalization of the peptide into cancerous cell lines, like C3H fibroblasts [92], although it has 
been noted that the RGD motif is not necessary for internalization in others, such as NIH3T3 
fibroblasts [93]. Lunasin also contains a carboxyl end with a 9 amino acid long poly D tail, whose 
negative charge is thought to allow its binding to positively charged hypoacetlyated histones in 
cancerous cells [93].  
 
1.10.2 Lunasin function 
Lunasin has been researched largely as a chemotherapeutic agent. It been suggested that 
lunasin contributes to the cancer preventive benefits of soy. The consumption of which is often 
associated with the lower cancer rates prevalent in South East Asian cultures [93]. Early work 
showed that the transduction of lunasin cDNA into a number of cancer cell lines could interrupt 
mitosis leading to apoptosis; these included murine hepatoma, human breast cancer, and 
murine embryo fibroblasts C3H 10T1/2 [91]. Other studies have demonstrated that the lunasin 
peptide can be used to significantly reduce the transformation rate of normal nontumorgenic 
C3H cells treated with carcinogenic agents or tumor inducing viral transfections [94]. The same 
studies showed that the lunasin peptide could be applied topically to reduce murine tumor 
incidents due to carcinogens like DBMA [94]. More recent work has shown that lunasin inhibits 
the growth of HT-29 colon cancer cells via a decrease in anti-apoptotic Bcl-2 proteins and an 
increase in the pro-apoptotic Bax, as well as in caspase 3, an enzyme common to apoptotic 
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processes [95]. Lunasin’s effect on histone acetylation is well documented. In one study a 
histone deacetylase inhibitor, sodium butyrate, was added to breast cancer cells with and 
without lunasin. The cells treated without lunasin had levels of acetylation several fold higher 
than the ones that had been treated with lunasin, the inference being that lunasin inhibited the 
acetylation of histones, thus preventing the activation of potentially oncogenic genes [94]. 
Around 4.5% of the total ingested lunasin can be detected in the human blood stream one hour 
after eating [96]. This suggests that lunasin is bioavailable and together with its observed 
antitumorgenic effect, indicates that lunasin may well contribute to the antitumor effect of soy. 
This antitumorgenic capacity of lunasin’s, as well as its immediate presence in the food supply 
makes it a promising choice for both clinical treatment and the widespread epidemiological 
prevention of cancer. 
 
1.11 Summary 
Natural killer cells are integral to the immune systems response to cancer. Since their 
identification our understanding of how NKCs recognize “missing self” has increased 
dramatically [4]. The manipulation of NKCs, though cytokine stimulation or receptor alteration, 
opens many new avenues of cancer treatments. In order to take full advantage of our 
understanding of NKCs capability new immunomodulators and cytokine combinations must be 
developed. Lunasin is a peptide known to have chromatin binding and anti-carcinogenic 
properties [93]. The use of lunasin and new treatments with NKCs open novel and promising 
new areas of cancer treatment.
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CHAPTER 2: MATERIALS AND METHODS
 
 
2.1 Cytokine, Antibodies, and Lunasin Peptides 
Recombinant human IL-2 was obtained from Prometheus Laboratories (San Diego, CA) and 
recombinant human IL-12 from PeproTech (Rocky Hill, NJ). Fluorochrome-conjugated 
monoclonal antibodies recognizing human CD3, CD4, CD8, CD14, CD56, and IFNγ were obtained 
from BD Biosciences (San Jose, CA). Ficoll-Paque
TM
 PLUS was purchased from GE Healthcare Bio-
Sciences (Piscataway, NJ). Antibodies against acetyl-histone H3 (AcH3), histone H3 trimethyl 
Lys9 (H3K9me3), and non-immune rabbit serum were obtained from Millipore (Billerica, MA). 
The lunasin peptide with 43-amino acid was chemically synthesized to 97% purity by LifeTein 
(South Plainfield, NJ), and includes the following sequence: 
SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDD. A truncated peptide (32-amino 
acids) lacking the RGD motif and the poly-D tail was synthesized by LifeTein, and includes the 
following sequence: SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQG. A negative control peptide 
with a scrambled sequence (RKMELQEGIHLKKGDQNTQSQSCQPKCIQVWH) was also synthesized. 
All the peptides were dissolved in sterilized water at stock concentration of 5 mM. FITC 
conjugated lunasin was purchased from LifeTein (South Plainfield, NJ). 
 
2.2 Human Blood Samples and Primary Cell Cultures 
Collection of blood samples was approved by the Institutional Review Board at Indiana 
University Medical Center and written informed consent was obtained from each study subject. 
Blood samples were obtained from patients with Hodgkin’s or non-Hodgkin’s lymphoma after 
treatment with high-dose chemotherapy and autologous Peripheral blood stem cell transplant 
(PBSCT). Healthy human blood samples were procured from the Indiana Blood Center 
(Indianapolis, IN). Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-
Paque
TM
 PLUS, and aliquots of PBMCs were cryopreserved in liquid nitrogen. Human NKCs were 
isolated from normal control PBMCs using positive selection with CD56 magnetic beads 
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(Miltenyi Biotech, Auburn, CA). Human B-lymphoma cell line Raji cell line was obtained from 
American Type Culture Collection (ATCC, Manassas, VA, USA). 
 
2.3 Evaluation of IFNγ Production 
IFNγ production at the single cell level was evaluated using intracellular cytokine staining. Cells 
were treated with 3µM (golgi stop) monensin sodium salt (Sigma-Aldrich, Saint Louis, Missouri) 
after stimulation with specific cytokine for 24 hours. Cells were then incubated with 
flurochrome-conjugated antibodies against CD3 and CD56 to mark surface antigens, fixed in 4% 
paraformaldehyde, and washed with permeablization buffer (0.1% saponin) before being 
incubated with the fluorochrome-conjugate anti IFNγ antibody. Total PBMCs were gated for 
CD3- and CD56+ populations, which were then analyzed for IFNγ production. Flow cytometry 
was performed using a FACSCalibur APC 4 color flow cytometer (BD Biosciences, Mountain View, 
CA) and analyzed using BD CellQuest
TM
 Pro version 6.0. Secreted IFNγ protein collected from the 
supernatant was measured using standard ELISA practices, as previously described [97, 98]. 
 
2.4 Analysis of Gene Expression 
Purified human NKCs were stimulated with medium only, lunasin at 20 μM, cytokine IL-12 at 10 
ng/ml or IL-2 at 100 units/ml, and cytokine plus lunasin for 24 hrs. One day following 
stimulation, the cell pellets were subjected to analysis of gene expression using real time qPCR 
with Taqman Assay Primers for IFNG, CSF2, GZMB, TGFB1, TGFBR2, CCL3, and CCL4. 
 
2.5 Analysis of STAT4 Activation by Western Blot 
Purified human NKCs were stimulated for 3 hours and 22 hours. Western blot analysis was 
performed from total protein extracts of cultured NKCs to measure the activation of STAT4 using 
an anti-phospho-STAT4 (Y693) antibody (Cell Signaling Technology, Danvers, MA). The same blot 
was reprobed with an anti-STAT4 monoclonal antibody (BD Biosciences, San Jose, CA) for the 
total amount of STAT4. Ratios of phospho-STAT4 to total STAT4 (pSTAT4/Total STAT) is 
determined from the arbitrary units using densitometry (calculated with ImageJ, U. S. National 
Institutes of Health, Bethesda, Maryland). An anti-β-actin monoclonal (SC-47778) antibody 
(Santa Cruz Biotechnology,Santa Cruz, CA) was used for the loading control.  
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2.6 In Vitro Cytotoxicity Assays 
Purified human NKCs stimulated as indicated for 1 day were washed and co-cultured with target 
cells (Raji) at the ratio of 10:1 for 4 hrs at 37C in a 5% CO2 incubator. NK-mediated lysis was 
analyzed using the CytoTox 96 non-Radioactive Cytotoxicity Assay Kit (Promega, Madison, WI). 
 
2.7 Adoptive Transfer of Human NKCs in Xenograft Model In Vivo 
The adoptive transfer of human natural killer cells into 2 months old NOD/SCID/gamma chain 
null (NSG) mice (The Jackson Laboratory, Bar Harbor, Maine) was performed by the In Vivo 
Therapeutics Core, Indiana University, Indianapolis. The mice were injected subcutaneously on 
day 1 with 0.5 x 10
6
 Raji cells in 0.1 ml PBS mixed with 0.1 ml Matrigel (BD Biosciences, San Jose, 
CA). Human NK cells isolated from healthy control donors were stimulated as indicated for 1 
day. On day 2, these pre-treated natural killer cells were injected at the tumor site (2.5 x 
10
6
/mouse). Tumor growth was monitored, and the volumes were measured using standard 
manual calipers. 
 
2.8 Chromatin Immunoprecipitation (ChIP) 
The ChIP experiment was performed using isolated human NKCs treated with medium only, IL-
12 (10 ng/ml), IL-12 (10 ng/ml) + lunasin (20 μM) or lunasin alone (20 μM) for 24 hours following 
the established protocol [99, 100].  
 
2.9 Confocal Staining 
NKCs were treated with FITC conjugated lunasin (20µM) and IL-12 (10 ng/mL) overnight in a 5% 
CO2 incubator at 37°C. NKCs were then dyed with DNA stain Hoechst 33342 (Thermo Scientific, 
Rcokford, IL) 0.5 mg/mL for 30 min in the same incubator prior to visualization at 400x. In a 
separate experiment NKCs treated under the same conditions were fixed in 4% 
paraformaldehyde and permabilized with ice cold 100% methanol. Histone H3 was identified 
using monoclonal antibodies (Cell Signaling, Danvers, MA) overnight at 4°C. Secondary 
antibodies, Alexa Fluor 555 (Cell Signaling, Danvers, MA), were incubated with the NKCs for 1-2 
hours at room temperature. Cells were visualized with a Fluoview FV 1000 confocal laser 
scanning microscope (Olympus, Center Valley, Pennsylvannia). 
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2.10 Statistical Analysis 
PASW Statistics (IBM-SPSS, Chicago, IL) was used to analyze the data. One-way ANOVA was 
employed to evaluate the difference of tumor volume among different groups followed by 
multiple rank comparisons with Tukey’s HSD test. Statistical significance was set at P ≤0.05. 
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CHAPTER 3: SOYPEPTIDE LUNASIN IN CYTOKINE IMMUNOTHERAPY FOR LYMPHOMA
 
 
3.1 Introduction 
The use of cytokines in addition to traditional cancer treatments can have a profound impact on 
the treatment of the disease. Numerous cytokines have been used in clinical trials to enhance 
anti-tumor immunity [101]. IFNγ has been noted as particularly important to the immune 
system’s response to a variety of tumors and virally infected cells [45-47]. Produced by T cells or 
NKCs, IFNγ activates macrophages [48], diminishes tumor growth [49], helps stimulate the 
maturation of dendritic cells [51], and is necessary in the early activation and differentiation of T 
helper cells [102]. Numerous cytokines are known to induce IFNγ production including IL-2, IL-
12, IL-15 and IL-18 which have been used individually and in concert [33, 41, 103, 104]. The 
induction of endogenous IFNγ is considered, by many, to be superior to exogenous injections 
due to the wide distribution of IFNγ receptors and as compared to cytokine receptors, like the 
IL-12R, which is largely confined to NK and T cells [105].  
IL-12, a potent inducer of IFNγ of in NKCs, signals through a STAT4 mediated pathway [101]. 
Earlier studies have established that patients treated heavily for cancer can acquire a STAT4 
deficiency[106]. The soypeptide lunasin, which has previously been touted for its anti-
carcinogenic effects, is explored here as a modulator of NKC activity and enhancer of IFNγ 
production. The goal of this study is to determine lunasin’s ability to modulate IFNγ production 
as well as to asses if it can overcome deficiencies in the cells of immune compromised patients. 
We found that lunasin in combination with cytokines could modulate NKC activity and 
significantly enhances the IFNγ production capacity of NKCs. This observation indicates that 
lunasin could be a therapeutic capable improving current cancer immunotherapies. 
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3.2 Results 
 
3.2.1 Lunasin Stimulates Human NKCs to Produce IFNγ 
IFNγ is a pro-inflammatory cytokine associated with the immune response to tumors, viruses, 
and bacterial infections [45-48]. Its prevalence in the immune response makes it an appropriate 
candidate for gauging NKC activity. PBMCs were treated with IL-2 or IL-12, known inducers of 
IFNγ [101], with and without lunasin. Fluorochrome conjugated antibodies were used to identify 
several cell population markers as well as IFNγ. Flow cytometry indicated that lunasin did not 
affect IFNγ production in CD4+ or CD8+ T cell populations, known producers of IFNγ, (data not 
shown), but did enhance IFNγ production by NKCs when in combination with cytokines IL-2 or IL-
12 (Figure 8A). This result was confirmed by measuring IFNγ levels in the supernatant of purified 
NKCs treated under the same conditions (Figure 8B). Using cells from the same culture qPCR was 
performed, and the mRNA levels of IFNG were higher in cells treated with both lunasin and 
cytokine as compared to cytokine alone (Figure 8C). That stimulation with both lunasin and 
cytokine, as opposed to lunasin alone, had such a prolific effect on IFNγ production, suggesting a 
synergistic mechanism of action. 
 
3.2.2 Lunasin Regulates Gene Expression in NKCs 
Along with IFNG, several other NKC genes appear to be affected by a lunasin-cytokine cocktail. 
qPCR results from samples obtained in Figure 8C show that adding lunasin to a treatment with 
either IL-12 or IL-2 significantly increases the expression of GZMB (granzyme B) and CSF2 
(Granulocyte-Macrophage Colony Stimulating Factor or GM-CSF), as compared to treatment 
with cytokine alone (Figure 9A). Stimulation with either IL-12 or IL-2 is known to downregulate 
TGFB1 and TGFBR2 expression in NKCs [107], and adding lunasin to cytokine-treated NKC 
cultures results in the further reduction of TGFB1 and TGFBR2 expression (Figure 9B). 
Interestingly lunasin was able to upregulate the expression of pro inflammatory chemokines CCL 
3 and CCL 4 without the need for additional cytokine stimulation (Figure 9C).  
 
3.2.3 Dose-Dependent Effects of Lunasin in Combination with Cytokines 
Lunasin was titrated against different concentrations of IL-2 and IL-12 in ordered to determine 
the best dose response. It was found that in the presence of lunasin lower concentrations of 
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cytokine could induce IFNγ production at levels similar to that of a 10 fold higher concentration 
(Figure 10A). This observation suggests that the addition of lunasin to a therapeutic cytokine 
treatment could allow the concentration of cytokine to be decreased without abating its 
stimulatory capacity. In order to determine the dose response of lunasin in the presence of 
cytokine, lunasin was titrated in combination with IL-12 10 ng/mL. The EC50 was determined to 
be 5.64 ± 1.94 μM (n=4) (Figure 10B).  
 
3.2.4 STAT4 Activation in Lunasin-Cultured NKCs 
IL-12 induces IFNγ production via the STAT4 transcription factor in NKCs [97, 108, 109]. IL-2, 
though a less potent inducer than IL-12, can also activate the STAT4 pathway [110]. In order to 
determine if lunasin was influencing STAT4’s activated form phosphorylated STAT 4 (pSTAT4) 
was assessed using western blots. Two time points were observed, 3 and 22 hours (Figure 11 A, 
B). IL-12 plus luansin stimulation elicited a higher amount of pSTAT4 than IL-12 alone at either 
time point. IL-2 showed a similar response though with much lower pSTAT4 levels than IL-12. 
The IL-12, IL-2, plus lunasin combination showed a similar amount of pSTAT4 compared to the 
two cytokines alone, at the earlier time point,, but had higher pSTAT4 levels at later time points. 
This result raises the possibility that lunasin’s aptitude for increasing IFNγ production, in 
combination with cytokines, is related to increasing the initial amount of STAT4 activated and 
possibly prolonging pSTAT4 activity. 
 
3.2.5 Effects of Lunasin Plus Cytokines on Rescuing IFNγ Production by NKCs from Lymphoma 
Patients Post-Transplant 
STAT4 deficiency as a result of cancer treatment has been observed in post-transplant patient 
PBMCs [111]. Lunasin’s ability to enhance, or perhaps prolong, the action of STAT4 means that it 
has the potential to nullify the deficiency created by cancer treatment. To test this hypothesis 
IFNγ production by the NKCs of healthy individuals was compared to IFNγ production by the 
NKCs of heavily treated post-transplant patients, deficient in STAT4. The results, as measured by 
flow cytometry, show that patient NKCs treated with both cytokines and lunasin produce a 
statistically equivalent (p=0.446) amount of IFNγ as compared to healthy cells treated with  
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cytokines alone (Figure 12). This finding implies that lunasin could serve to augment IFNγ 
production in patients receiving cytokine immunotherapy who have an acquired STAT4 
deficiency. 
 
3.2.6 Lunasin Augments the Cytotoxicity of Cytokine-Activated NKCs 
To determine if the lunasin-cytokine combination that increases IFNγ production (Figure 8 A-C) 
also increases NKC cytotoxic activity, an in vitro cytotoxicity assay was utilized. Results show that 
NKCs treated with lunasin and cytokines together lyse Raji cells, a B lymphoma cell line usually 
resistant to NKCs, more effectively than NKCs treated with cytokines alone (Figure 13A). 
Cellular therapies employing NKCs have been clinically tested for several cancer types including 
acute myeloid leukemia, renal carcinoma, and malignant melanoma [15, 75]. In these therapies 
NKCs are stimulated and expanded ex vivo before being infused into the patients. In vitro 
cytotoxicity assay results indicate that the addition of lunasin to IL-2 or IL-12 cytokine 
treatments makes NKCs more capable of lysing tumor cells (Figure 13A) and better able to 
produce IFNγ (Figure 8 A-C). Such results suggest that lunasin-cytokine stimulation is a superior 
NKC activator for cellular therapies. In order to determine if the addition of lunasin to cytokine 
treatments can enhance NKC tumor fighting capacity in vivo, a xenographt model was utilized. 
Raji, B cell lymphoma, cells were injected into NSG (NOD/SCID/gc
null
) mice. A day later the mice 
were infused with human NKCs stimulated with various combinations of lunasin and cytokines. 
The results show that mice treated with both lunasin and cytokine develop smaller tumors than 
mice treated with cytokine alone (Figure 13B). 
 
3.2.7 Lunasin’s RGD Sequence is Not Required for NKC Stimulation 
Lunasin’s RGD sequence has been identified as the sequence through which lunasin adheres to 
and is consequently able to enter some cancer cell lines [94]. NKCs also express integrins 
capable of binding the RGD motif [92], which allows for the possibility that lunasin enters NKCs 
in a similar fashion. To determine if this was the case, a mutant peptide (Figure 14A), lacking the 
RGD sequence and the aspartic acid tail, was evaluated for its ability to stimulate NKCs. The 
results show that the mutant peptide and wild type lunasin have equivalent stimulatory capacity 
(Figure 14B). Therefore it was determined that lunasin’s effect on NKCs does not rely on its RGD 
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motif. In addition, the scrambled negative peptide did not induce detectable levels of IFNγ 
(Figure 14B), which ruled out the non-specific effects at the concentrations used (20 μM). 
3.2.8 Mechanism of Synergistic Effects Mediated by Lunasin 
Lunasin’s apparent ability to affect NKCs without an RGD motif suggested that it may not be 
entering NKCs at all and perhaps binding to some unknown surface receptor [94, 112]. To 
determine if lunasin was entering the cell, NKCs were incubated with FITC conjugated lunasin 
and IL-12 10 ng/mL overnight and were stained with a Hoechst DNA stain 30 minutes prior to 
visualization. The results show that lunasin is present within both the cell and its nucleus (Figure 
15A). Additionally NKCs, treated under the same conditions, were incubated with a histone 
antibody (Figure 15B). The results again indicate that lunasin is able to pass both the cellular and 
nuclear membranes. 
The acetylation of histone H3, AcH3, is a well-recognized mark of an active gene locus [113]. It 
has been reported that lunasin can inhibit histone acetyltransferase (HAT) activity [112] as well 
as bind to deacetylated histones in cancer cell lines [94]. Lunasin’s capacity to work 
synergistically with IL-2 and IL-12 to affect multiple genes (Figures 8C, 9), its presence in the 
NKC’s nucleus (Figure 15), and its ability to alter the acetylation of histones in other cell types 
[91, 112], all indicate an epigenetic mechanism. To test this hypothesis a ChIP assay was 
performed to evaluate changes in AcH3 at the IFNG locus after stimulation with a cytokine-
lunasin cocktail and cytokine alone (Figure 16). NKCs treated with a cytokine-lunasin mix showed 
higher levels of acetylation at the IFNG locus gene than cytokine alone. IL-12 suppresses TGFB1 
expression in NKCs, and stimulation with both IL-12 and lunasin further reduces TGFB1 
expression (Figure 9B upper panel). The acetylation of histone H3 at the TGFB1 locus follows this 
trend, with less acetylation at the TGFB1 locus in NKCs treated with both cytokine and lunasin. 
These results indicate that lunasin is able to modulate the AcH3 at target gene loci. 
Histone mark H3K9me3, tri-methylated histone H3 at lysine 9, is commonly associated with 
transcriptional repression [114]. Using ChIP, H3K9me3 was examined at the IFNG and TGFB1 loci 
but no alterations in methylation, regardless of stimulation of IL-12 or lunasin, were found 
(Figure 16B). This suggests that IL-12 does not alter H3K9me3 levels at these loci, and the 
addition of lunasin generates no additional effects. 
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3.3 Discussion 
Lunasin is a 43 amino acid peptide present in wheat, barley, and soybean [90]. It has been 
touted largely for its cancer preventative properties [90, 112, 115], relatively little research, 
however, has been done on how lunasin affects immune cells. This study explores the use of 
lunasin as an immunomoduatory agent and specifically addresses how lunasin and selected 
cytokines alter NKC behavior. Lunasin was used in varying combination with IL-2 and IL-12. The 
combination of lunasin and selected cytokine, lunakine, was found to have significant 
immunomodulatory effects, which include increasing IFNγ production and the natural 
cytotoxicity of NKCs (Figures 8, 12). Lunakine accomplishes this immunomodulation through the 
upregulation of a number of genes needed for NKC activity (Figure 8C, 9) via what is most likely 
an epigenetic mechanism. Lunakine’s ability to enhance NKC activity makes it a novel 
therapeutic and a promising new biologic for cytokine based therapies. 
IFNγ is a pro inflammatory cytokine necessary for effective immunosurveillance [116]. It has 
been noted for its ability to inhibit angiogenesis [117], and has been linked to the development 
of CD4+ T helper type 1 (Th1) cells [118, 119]. The production of IFNγ and the lysis of target cells 
are two of the primary functions of NKCs. Additionally, NKCs produce GM-CSF, which has pro 
inflammatory and immune cell recruitment and development properties. NKC stimulation by 
lunakine induces enhanced production of GM-CSF and IFNγ, as well as the chemokines CCL3 and 
CCL4 (Figures 8, 9). All of which creates an unfavorable environment for tumor growth. 
Lunasin was titrated against different concentrations of IL-2 and IL-12. It was found that in the 
presence of lunasin lower concentrations of cytokine could induce IFNγ production at levels 
similar to that of a 10 fold higher concentration (Figure 10A). In order to determine the dose 
response of lunasin in the presence of cytokine, lunasin was titrated in combination with IL-12 
10 ng/mL. The EC50 was determined to be 5.64 ± 1.94 μM (n=4) (Figure 10B). This result suggests 
that the addition of lunasin to a therapeutic cytokine treatment could allow the concentration 
of cytokine to be decreased without abating its stimulatory capacity. 
Previous studies have indicated that heavily treated bone marrow transplant and chemotherapy 
patients acquire a STAT4 deficiency, which leads to impaired IFNγ production [98, 106]. IL-12 
induces IFNγ production via the STAT4 transcription factor in NKCs and T cells [97, 108, 109]. 
STAT4 is deficient but not null in these patients which is why the stimulation of PBMCs with IL-
12 still leads to IFNγ production, though at lower levels than in healthy cells [120]. Flow 
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cytometry indicates that, when treated with lunakine, STAT4 deficient cells can be induced to 
produce IFNγ at similar levels to that of normal cells treated with cytokines alone (Figure 12). 
Given the lunakine’s ability to enhance IFNγ production in STAT4 deficient PBMCs it is possible 
that lunakine could enhance the immune system of recovering cancer patients who have 
undergone chemotherapy or bone marrow transplants and acquired a STAT4 deficiency. 
Along with cytokine production, the lysis of tumor cells is one of the main functions of NKCs. 
One way that NKCs accomplish this task is through the release of lytic granules containing, 
among other things, a serine protease called granzyme B [121]. Granzyme B is constitutively 
expressed in NKCs and can be up-regulated by multiple cytokines including IL-12 and IL-2 [81, 
122]. Adding lunakine upregulates GZMB expression more than either IL-2 or IL-12 alone (Figure 
9A, upper panel). Such upregulation is corroborated by cytotoxicity assays which demonstrate 
that NKCs stimulated with lunakine have more killing capacity than NKCs stimulated cytokine 
alone (Figure 13A). These results have implications on adoptive cellular therapies which require 
the ex vivo stimulation of cells. NKC based cellular therapy has been employed clinically for 
several cancer types including acute myeloid leukemia, renal carcinoma, and malignant 
melanoma [15, 75]. In order to determine if lunakine stimulation could be applied to this type of 
therapy a xenographt model, using NSG mice, was utilized. The mice were infused with a human 
B cell lymphoma, Raji, followed by human NKCs a day later. The results showed that mice 
injected with lunakine treated NKCs were best able to fight tumor growth (Figure 13B), 
supporting its potential use in cellular therapy. 
Lunasin’s mechanism of action is still uncertain, but there are numerous pieces of data 
suggesting that it is epigenetic in nature. Lunasin works synergistically with cytokines to alter the 
expression of several genes (Figure 8C, 9). The modulation of multiple genes suggests an 
underlying mechanism. IL-12 and IL-2 induce IFNγ production by NKCs, but show an enhanced 
production capacity when added together with lunasin (Figure 8 A-C). Lunasin by itself shows 
little ability to induce IFNγ production. GZMB and CSF-2 (GM-CSF) expression is upregulated in 
NKCs stimulated with IL-12 or IL-2, but is enhanced even more with the addition of lunasin 
(Figure 9A), while lunasin alone is comparatively ineffective. TGFB1 is downregulated by IL-12 
[107], and once again lunasin seems to enhance this effect (Figure 9B upper panel). Lunasin’s 
ability to work synergistically to enhance cytokine action but not induce strong results of its own 
indicates that it is somehow stabilizing or prolonging the effect of these cytokines. This type of 
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synergy is not always the case however. It should be noted that lunasin alone is able to 
upregulate CCL3 and CCL4 chemokines (Figure 9C), indicating that lunasin has many yet 
undefined properties. 
IL-12 signals through a STAT4 pathway and is required for IFNγ production [97, 108, 109] and IL-
2, though a less potent inducer than IL-12, can also activate the STAT4 pathway [110]. Because 
lunasin enhances the effect of IL-12 (Figure 8 A-C) it is possible that increased STAT4 activation is 
involved in the synergistic induction of IFNγ. Activated STAT4 (pSTAT4) was measured over two 
time points. Both the 3 and 22 hour time points showed an increase in pSTAT4 levels when 
treated with lunasin, for either IL-2 or IL-12 conditions (Figure 11 A, B). The IL-12 plus IL-2 
condition had similar levels of pSTAT4 as compared to the two cytokines plus lunasin at the early 
time point but the condition with lunasin had higher pSTAT4 levels at the later time point. This 
result suggests that adding lunasin to cytokine stimulation can enhance over all STAT4 activation 
in cytokine treated cells, and that this enhancement can last well after the initial stimulation. 
Numerous cell types, including NKCs and cancer cell lines, have integrins capable of binding to 
lunasin’s RGD motif [92]. It has been noted in earlier studies that lunasin enters some cancer cell 
lines via this motif [94]. In order to determine if lunasin was entering NKCs in the same manner, 
a mutant peptide with no RGD sequence was produced (Figure 14A) and used to stimulate NKCs. 
The results showed no difference between the mutant and the wild type lunasin (Figure 14B), 
indicating that the RGD motif was not a required part of lunasin’s mechanism. In order to 
determine if lunasin was entering the cell, NKCs were stimulated with FITC conjugated lunaisn 
and IL-12 (10 ng/mL) overnight and stained with a Hoechst DNA stain 30 minutes prior to 
visualization. The results indicate that lunasin can pass both the plasma and nuclear membrane 
of NKCs (Figures 15 A, B).  
The acetylation of histone H3, AcH3, is a well-recognized mark of an active gene locus [113]. It 
has been reported that lunasin can bind to histone acetyltransferases (HATs) [112] as well as to 
deacetylated histones in cancer cell lines [94]. Lunasin’s capacity to work synergistically with IL-2 
and IL-12 to affect multiple genes (Figure 8C, 9), its localization to the NKCs nucleus (Figure 16), 
and its ability to alter the acetylation of histones in other cell types [91, 112], all indicate a likely 
epigenetic mechanism. To test this hypothesis, a ChIP assay was performed to evaluate changes 
in AcH3 at the IFNG locus after stimulation with lunakine and cytokine alone (Figure 16A). NKCs 
treated with lunakine show higher levels of acetylation at the IFNG locus than cytokine alone. IL-
26 
12 suppresses TGFB1 expression in NKCs, and stimulation with lunakine further reduces TGFB1 
expression (Figure 9B upper panel). The acetylation of histone H3 at the TGFB1 locus follows this 
trend, with less acetylation at the TGFB1 locus in NKCs treated with lunakine, as compared to 
cytokine alone. These results indicate that lunasin is able to modulate the AcH3 at target gene 
loci, created by initial cytokine exposure such as IL-12, thereby enhancing or prolonging the 
activation of target genes. To support this notion, we observed minimal amounts of the 
repressive H3K9me3 modification at either locus (Figure 10B) regardless of treatment with 
cytokine or lunakine, suggesting that H3K9me3 is not involved in IL-12-mediated gene regulation 
in NK cells, and adding lunasin has no effects on H3K9me3 to these loci. 
Questions remain as to exactly how lunasin enters NKCs and precisely how it is augmenting the 
epigenetic state initiated by cytokine stimulation. These issues require further study. What is 
clear is that lunasin enhances the effect of cytokines on NKCs isolated from PBMCs. This finding 
indicates that lunasin could be used to increase the efficacy of cytokine based therapies without 
increasing the concentration of cytokines and risking toxic consequences.  
 
3.4 Future Directions 
There is still a great deal to be discovered about the effects of the soypeptide lunasin on 
immunological systems. In this paper it was proposed that lunakine prolongs the activating 
effects of STAT4 on IFNγ production. It was also noted, however, that lunasin alone was enough 
to induce the production of chemokines CCL3 and CCL4 (Figure 9C). The enhancement of 
chemokine production could generate significant immunoregulatory potential, and thus 
warrants further study. The enhancement of already existing immunotherapies is one of 
lunakine’s most promising areas of use. In this study it was shown that lunasin can rescue IFNγ 
production in STAT4 deficient human PBMCs In Vitro (Figure 12). The next step is to utilize 
lunasin in mouse immunotherapy models, in which mice recovering after cancer treatment, or 
with a STAT4 deficiency, receive lunakine infusions. Lunasin would seem to have many 
applications as an immunomodulator which is relevant for individuals with compromised  
immune systems, and particularly those receiving cytokine therapy. The further study of its 
effects under various conditions with different cytokines may yet yield new and innovative 
treatments. 
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Figure 1. “Missing-self”. Graphic depiction of encounters between NK cells and potential targets 
and possible outcomes. In some circumstances, inhibitory receptors recognizing ligands other 
than MHC class I proteins may suppress NK cell responses. When interacting with target cells 
expressing ligands for both inhibitory and activating receptors, the outcome is determined by 
the summation of the strength of signals. The amount of activating and inhibitory receptors on 
the NK cells and the amount of ligands on the target cell, as well as the qualitative differences in 
the signals transduced, determine the extent of the NK cell response. Figure from Lanier [4].
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Figure 2. Human NK receptors (and their signaling adapters) for MHC class I. Figure from Lanier 
[4]. 
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Figure 3. The JAK/STAT Signaling Pathway. When a cytokine ligates its receptor the cytokine 
receptor’s associated JAKs become activated. The JAKs mediate the phosphorylation of tyrosine 
residues and recruited STATs. Activated (phosphorylated) STATs are released from the receptor, 
dimerize, and translocate to the nucleus where they bind to gamma associated sites (GAS) and 
initiate gene transcription. Figure from Kisseleva [35]. 
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Figure 4. Receptor Families and JAK/STAT Pathways. Figure from Kisseleva [35]. 
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Figure 5. Death Receptor Apoptosis. Fas (CD95) is used as an example for the purpose of 
demonstating the extrinsic apoptotic pathway. The FasL (Fas ligand) on the immune cell will 
ligate a Fas receptor on the target cell. The ligation will trigger the binding of FADD, an adaptor 
protein, which will in turn associate with procaspase-8. A DISC, the death inducing signaling 
complex, will then form and cleave procaspase-8 leading to its activation, followed by the 
activation of caspase-3, a potent catalyst in the cleavage of cellular proteins, ultimately leading 
to cell death [60-63]. Figure from Siegel [123]. 
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Figure 6. Granzyme B Apoptosis. Perforin is generally recognized as providing the mechanism for 
granzyme to enter the cell, though the exact method through which it does this remains a 
subject of debate [65]. Once in the cell’s cytoplasm granzyme B can work though several 
pathways including the direct activation of caspase 3, which leads to apoptosis, and the 
disruption of the mitochondrial membrane which leads to the release of cytochrome c and the 
eventual activation of caspase 3. Figure from Lieberman [124]. 
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Figure 7. Cellular Sources and Responders of IL-12. Antigen-presenting cells and phagocytic cells, 
including monocytes and macrophages, dendritic cells, and neutrophils, are the primary 
producers of IL-12. The major actions of IL-12 are on T and NK cells. IL-12 induces proliferation, 
interferon production and causes increased cytotoxic activity in these cells. Additionally, IL-12 
induces the differentiation of CD4+ T cells to the Th1 phenotype which is important in pro 
inflammatory responses. Figure from Watford [105].  
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Figure 10. Dose-dependent Effects of Lunasin in Combination With Cytokines. (A) EC50 was 
calculated using the dose response curve function of OriginPro 8.1. NKCs were stimulated with 
IL-12 10 ng/mL and a half fold lunasin dilution series overnight. The production of IFNγ in the 
supernatants was determined using ELISA. (B) Human NKCs isolated as described in figure 8B 
were stimulated with single or both cytokines at low or high doses in the combination with 
different concentrations of lunasin. One day following stimulation, the production of IFNγ in the 
supernatants was determined using ELISA. Data are presented as mean ± SD from duplicates. 
Results shown are representative from over 3 different normal controls.  
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Figure 11. pSTAT4 at Different Time Points After Lunasin-cytokine Stimulation. Human NKCs 
were isolated as described in figure 8B and then stimulated with single or both cytokines at low 
or high doses in combination with lunasin. Activation of STAT4 was determined using western 
blot of total protein extracts from cultured NKCs. Ratios of phospho-STAT4 to total STAT4 
(pSTAT4/Total STAT4) are indicated. (A) NKCs were stimulated for 3 hours. (B) NKCs were 
stimulated for 22 hours. Densitometry determined using ImageJ, U. S. National Institutes of 
Health, Bethesda, Maryland. 
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Figure 14. Mechanisms of Synergistic Effects Mediated by Lunasin
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 Figure 15. Lunasin Enters the Nucleus of NKCs
FITC conjugated lunasin (20 µM )(green) overnight. (A) Hoechst 33342 DNA stain (0.5 
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Figure 16. Chromatin Remodel
(described in Figure 8B) were stimulated with medium only (
+ lunasin (20 μM) or lunasin alone (20 μM). Following 1 day of stimulation, cells were subjected 
to the ChIP assay. Chromatin DNA fragments were immunoprecipitated with antibodies against 
acetyl-histone H3 (AcH3) (A) 
immune rabbit serum (filled bars) (Millipore, Billerica, MA), individually. T
histone modification of IFN
Assay for human IFNG (+1kb) and 
CA). For calculation of ChIP results, the amount of 
input chromatin in each reaction as a percentage of input (% input). Data are shown as mean % 
of input ± SD from duplicates. Results are representative from 3 different controls. *P<0.05 
relative to NK stimulated with IL
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 APPENDIX
Figure A1. Lunasin in the Endoplasmic Reticulum.
(10 ng/mL) and FITC conjugated lunasin (green) from LifeTein (South Plainfield, NJ). NKCs were 
fixed in 4% paraformaldehyde and permabilized with ice cold 100% methanol. Calnexin (red), a 
protein associated with the endoplasmic reticulum, was stained using primary monoclonal 
antibodies from Cell Signaling (
555) were incubated with the NKCs for 1
 
Figure A2. Lunasin in the Autophagosome.
ng/mL) and FITC conjugated lunasin (green) from LifeTein (South Plainfield, NJ). NKCs were fixed 
in 4% paraformaldehyde and permabilized with ice cold 100% methanol. Autophagosome H3 
(red) was stained using primary monoclonal antibodies from Cell Signaling
overnight at 4°C. Secondary antibodies (Alexa Fluor 555) were incubated with the NKCs for 1
hours at room temperature. 
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